What is the difference between Opdivo and Keytruda?
Opdivo (nivolumab) and Keytruda (pembrolizumab) are two immunotherapy drugs for various cancers. Both are monoclonal antibodies, known as PD1 inhibitors, first approved in 2014. Opdivo is from Bristol Myers Squibb, and Keytruda is from Merck & Co.
The main differences lie in dosing, combination therapies, and approved cancer types.
Opdivo Vs Keytruda Dosing Frequency
Opdivo: Given via 30-60 min IV infusion every 2-4 or 6 weeks.
Keytruda: Given via 30 min IV infusion every 3-6 weeks.
Opdivo Vs Keytruda Combination Therapy
Opdivo is used with drugs like:
- Ipilimumab (Yervoy)
- Carbozantinib (Cabometyx)
- Cisplatin (Platinol)
- Gemcitabine (Infugem).
Keytruda is used with drugs like:
- Pemetrexed (Alimta) and platinum chemotherapy
- Carboplatin (Paraplatin) and either paclitaxel or paclitaxel protein-bound (Abraxane)
- Platinum and flurouracil
- Trastuzumab (Herceptin) plus fluoropyrimidine- and platinum-containing chemotherapy
- Axitinib (Inlyta)
- Lenvatinib (Lenvima)
- Chemotherapy.
Both drugs are also used alongside fluoropyrimidine- and platinum-containing chemotherapy for treating certain gastric cancers.
Related questions
- How long does it take for Keytruda to work?
- What is the success rate of Keytruda?
- What are monoclonal antibodies?
Opdivo Vs Keytruda Approved Uses
Keytruda is approved for additional cancer types, including non-small cell lung cancer (as a first-line treatment), cervical cancer, Merkel cell carcinoma, Primary mediastinal large B-cell lymphoma, endometrial carcinoma, biliary tract cancer, tumor mutational burden-high cancer, and triple-negative breast cancer.
Opdivo was the first for adjuvant treatment of high-risk urothelial carcinoma, and is also used for pleural mesothelioma (cancer that affects the lining of the lungs and chest wall), and colorectal cancer.
Both are used for various other cancers, including:
- skin cancers
- lung cancer
- kidney cancer
- classical Hodgkin lymphoma
- cancer of the stomach and esophagus
- squamous cell cancer
- bladder cancer
- liver cancer.
*There are slight differences in approval specifics between Opdivo and Keytruda, such as if they are approved first-line or just for advanced (metastatic) cancer.
References
- Opdivo Product Label. Updated 03/2024 https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208464s016s017lbl.pdf
- Keytruda Product Label. Updated 10/2023. https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf
Read next
Related medical questions
- How are Inlyta and Keytruda used in kidney cancer?
- How is pembrolizumab (Keytruda) administered?
- Is lenvatinib / pembrolizumab used in endometrial cancer?
- Is Xalkori the same as Opdivo or Keytruda?
- What are biologic drugs and how do they work?
- How long does Opdivo prolong life and what’s its success rate?
- How long does Opdivo take to work and how do you know if it's working?
- How long does Opdivo stay in your system?
- What happens when you stop taking Opdivo for melanoma?
- Is Opdivo a chemotherapy or immunotherapy drug?
- How are Opdivo and Yervoy administered?
- Is Opdivo approved for treating bladder cancer?
Drug information
Related support groups
- Keytruda (18 questions, 62 members)
- Opdivo (16 questions, 52 members)
- Non-Small Cell Lung Cancer (52 questions, 70 members)
- Renal Cell Carcinoma (30 questions, 102 members)
- Melanoma (18 questions, 50 members)